Sector News

GE Healthcare adds to cell therapy portfolio by acquiring Asymptote

April 12, 2017
Life sciences

GE Healthcare said today it has acquired Asymptote for an undisclosed price in a deal that the buyer said would strengthen its cell therapy portfolio with technologies designed to enable the cryopreservation of cellular materials.

Asymptote specializes in cryochain technology for sensitive cellular therapies, with the goal of significantly lowering the risk of contamination found in conventional processes.

The company’s integrated suite of cryochain hardware, software, and consumables is designed to support cGMP and maintain the potency of cellular therapies by enabling ultra-low-temperature freezing during production, followed by thawing prior to administering to patients in clinical settings.

Asymptote’s VIA FreezeTM range delivers liquid nitrogen-free cryopreservation, while the soon-to-be released VIA ThawTM series thaws deeply frozen cells using a dry conduction (water-free) process. The company’s web-based my.Cryochain software platform is designed to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, improving the visibility of remote processes.

“Asymptote’s high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world,” Ger Brophy, Ph.D., general manager of GE Healthcare’s cell therapy business, said in a statement.

Added Asymptote founder and CEO John Morris, Ph.D.: “The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development.”

GE Healthcare reasons that demand for manufacturing and clinical delivery will increase as the cell therapy market grows and develops. The company cited statistics from the Alliance for Regenerative Medicine showing 804 clinical trials underway by the end of last year for cell therapies, as well as gene-modified cell therapies, gene therapies, and tissue-engineering therapies.

The acquisition of Asymptote is GE Healthcare’s latest move toward growing its cell therapy offerings. In July 2016, GE acquired Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed sum. Three months earlier, GE Ventures teamed up with Mayo Clinic Ventures to launch Vitruvian Networks, a collaboration providing cloud-based software systems and manufacturing services for cell and gene therapies.

And in January 2016, GE Healthcare and the Government of Canada each committed C$20 million ($15 million) to launch the BridGE@CCRM Cell Therapy Centre of Excellence, created to promote new technologies for the production of cellular therapies in Toronto.

Source: GEN

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]